|Systematic (IUPAC) name|
3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
|ATC code||C08CA02 (WHO)|
|Molar mass||384.259 g/mol[[Script error: No such module "String".]]|
|Script error: No such module "collapsible list".|
Felodipine is a calcium channel blocker (calcium antagonist), a drug used to control hypertension (high blood pressure). It is marketed under the brand name Plendil by AstraZeneca and Renedil by Sanofi-Aventis. The formulation patent for the substance expired in 2007.
AstraZeneca dropped Plendil from its support and AZ&Me free Rx access program in October 2008.
Recent findings have suggested that felodipine in combination with grapefruit juice can cause toxic effects. Oral administration of felodipine is first metabolized in the gastrointestinal tract and liver by the enzyme CYP3A4. Grapefruit juice contains bergamottin which is found to have an inhibiting effect over this enzyme and as a result the bioavailability of the drug increases, raising the risk for abnormal side effects. 
Contraindications and cautions
contraindicated with allergy to felodipine or other calcium channel blockers, sick sinus syndrome, heart block(second and third degree, lactation. use cautiously with pregnancy, impaired hepatic function.
Berntsson, P. B.; Carlsson, A. I.; Gaarder, J. O.; Ljung, B. R.; 1981, U.S. Patent 4,264,611.
Cite error: Invalid
parameter "group" is allowed only.
<references />, or
<references group="..." />
|30px||This drug article relating to the cardiovascular system is a stub. You can help ssf by expanding it.|
- AstraZeneca MI Department, 16th April 2010
- Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.